Literature DB >> 21190993

Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.

Shunya Arai1, Akihide Yoshimi, Munetake Shimabe, Motoshi Ichikawa, Masahiro Nakagawa, Yoichi Imai, Susumu Goyama, Mineo Kurokawa.   

Abstract

Ecotropic viral integration site-1 (Evi-1) is a nuclear transcription factor that plays an essential role in the regulation of hematopoietic stem cells. Aberrant expression of Evi-1 has been reported in up to 10% of patients with acute myeloid leukemia and is a diagnostic marker that predicts a poor outcome. Although chromosomal rearrangement involving the Evi-1 gene is one of the major causes of Evi-1 activation, overexpression of Evi-1 is detected in a subgroup of acute myeloid leukemia patients without any chromosomal abnormalities, which indicates the presence of other mechanisms for Evi-1 activation. In this study, we found that Evi-1 is frequently up-regulated in bone marrow cells transformed by the mixed-lineage leukemia (MLL) chimeric genes MLL-ENL or MLL-AF9. Analysis of the Evi-1 gene promoter region revealed that MLL-ENL activates transcription of Evi-1. MLL-ENL-mediated up-regulation of Evi-1 occurs exclusively in the undifferentiated hematopoietic population, in which Evi-1 particularly contributes to the propagation of MLL-ENL-immortalized cells. Furthermore, gene-expression analysis of human acute myeloid leukemia cases demonstrated the stem cell-like gene-expression signature of MLL-rearranged leukemia with high levels of Evi-1. Our findings indicate that Evi-1 is one of the targets of MLL oncoproteins and is selectively activated in hematopoietic stem cell-derived MLL leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190993     DOI: 10.1182/blood-2009-07-234310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.

Authors:  Yi Zhang; Kristina Owens; Layla Hatem; Carolyn H Glass; Kannan Karuppaiah; Fernando Camargo; Archibald S Perkins
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

2.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

Review 3.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

5.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

6.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Authors:  A V Krivtsov; M E Figueroa; A U Sinha; M C Stubbs; Z Feng; P J M Valk; R Delwel; K Döhner; L Bullinger; A L Kung; A M Melnick; S A Armstrong
Journal:  Leukemia       Date:  2012-12-13       Impact factor: 11.528

7.  EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Mio Kajihara; Daisuke Tomizawa; Tomoyuki Watanabe; Akiko Moriya Saito; Junichiro Fujimoto; Keizo Horibe; Kumi Kodama; Mayu Tokumasu; Hiroshi Itoh; Hideki Nakayama; Akitoshi Kinoshita; Takashi Taga; Akio Tawa; Tomohiko Taki; Norio Shiba; Kentaro Ohki; Yasuhide Hayashi; Yuka Yamashita; Akira Shimada; Shiro Tanaka; Souichi Adachi
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

Review 8.  ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Authors:  Jianbiao Zhou; Yvonne Ng; Wee-Joo Chng
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

Review 9.  Epigenetics and B-cell lymphoma.

Authors:  Rita Shaknovich; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 10.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.